Launching a Private Label Intimate Care Line in the EU: Regulatory Checklist

Under Regulation (EC) No 1223/2009 every cosmetic product placed on the EU market must have a designated Responsible Person established in the Union. That legal or natural person guarantees compliance, holds the Product Information File, performs the notification and is the contact point for authorities.

For a private label line the Responsible Person is usually the brand owner when it is established in the EU, or the importer when the brand is outside the Union. The role can be assigned by written mandate, but it cannot be assumed informally: the responsibility is explicit and it is legally significant.

Agreeing who holds this role, in writing, is the first item on any launch checklist — before samples, before packaging, before marketing.

The Product Information File, or PIF, is the dossier that must be kept available to authorities for ten years after the last batch is placed on the market. It is the backbone of compliance and the document a serious retail or pharmacy buyer will ask about.

A complete PIF for an intimate care product includes:

Part B of the safety report must be signed by a qualified safety assessor holding the qualifications set out in the Regulation — typically a degree in pharmacy, medicine, toxicology or a comparable discipline. The assessor evaluates the toxicological profile of each ingredient, exposure, the intended use and the target population.

For intimate care this evaluation deserves particular attention. The application site is a sensitive, more permeable area, exposure is frequent, and the audience often includes women in the postpartum period or in menopause. A well-written assessment reflects those realities rather than treating the product as a generic body cosmetic.

The assessor's conclusions may also constrain the formula: a maximum concentration, a fragrance restriction, a labelling warning. Those constraints should be received before packaging artwork is finalised.

Before a product is placed on the EU market, the Responsible Person notifies it through the Cosmetic Products Notification Portal, the CPNP. The notification covers the product identity, category, the Responsible Person, the country of first placing, the frame formulation and information needed by poison centres, along with the label and, where relevant, a product photograph.

The notification is not an approval. Nobody reviews and authorises a cosmetic product before launch in the EU; the system is built on the Responsible Person's accountability and on market surveillance by national authorities.

Distributors who place a product on the market in another Member State under their own name, or who modify a notified product, take on additional obligations — a point that often surprises brands expanding across borders.

Article 19 of the Regulation sets out the mandatory labelling elements: the name and address of the Responsible Person, the nominal content, the date of minimum durability or the period-after-opening symbol, particular precautions for use, the batch number, the product function where it is not obvious, and the list of ingredients using INCI nomenclature, headed by the word 'Ingredients'.

Language requirements are national. Each Member State decides which language the consumer-facing elements must appear in, which matters when a private label line is destined for several markets from a single production run.

For intimate care, the function statement and the precautions deserve extra thought: clarity that the product is for external use on the vulvar area avoids both consumer confusion and regulatory ambiguity.

Manufacturing must comply with good manufacturing practice; compliance is presumed when production follows the harmonised standard EN ISO 22716. A private label buyer should expect the manufacturing site to work to that standard and to supply batch documentation accordingly.

The testing plan behind the file typically covers stability, packaging compatibility, preservative efficacy through challenge testing, and tolerance on human volunteers under dermatological — and often gynaecological — supervision. Claim substantiation studies are added where the marketing requires them.

Animal testing of finished cosmetic products and their ingredients is banned in the EU, as is the marketing of products so tested, under the same Regulation.

In a typical private label project the laboratory develops the formulation, runs the testing plan, manufactures under GMP and compiles the technical content of the file. The brand owns positioning, artwork, claims strategy and the commercial decisions, and — when it is the Responsible Person — signs off compliance and holds the dossier.

Difficulties usually arise in the grey zone between the two: who approves the final claim wording, who commissions a claim substantiation study, who updates the notification when a shade or a fragrance changes, and who keeps the artwork version aligned with the notified label. Naming an owner for each of these at the start of the project prevents the most common launch delays.

A written specification per reference — formula code, pack, fill weight, label version, notification reference, batch documentation — is the practical tool that keeps a multi-reference line coherent across repeat production runs.

For a straightforward line built on an existing formulation base, dossier preparation and notification typically run in parallel with the final sampling rounds, and the whole programme fits within twelve to twenty weeks from an approved brief. The pacing constraints are usually stability testing and, where required, tolerance studies on volunteers.

Custom development takes longer, because each new formula needs its own safety assessment, its own stability data and its own preservation validation. Adding a market outside the EU adds a further layer: labelling languages, local registration and, in some jurisdictions, ingredient restrictions that differ from the EU annexes.

The practical rule is to freeze the formula and the pack before artwork is printed. Every change after that point ripples through the safety assessment, the label and the notification.

Two frameworks outside cosmetics law frequently apply. Packaging must respect EU packaging and waste obligations and national extended-producer-responsibility schemes. If the line is sold online in the EU, the processing of customer data falls under Regulation (EU) 2016/679, the GDPR, which also governs the consent wording on a brand's own enquiry forms.

Finally, post-market duties continue after launch: serious undesirable effects must be reported to the competent authority, and the Responsible Person must keep the PIF current as formulations, suppliers or claims evolve.

A well-run private label project delivers all of this as part of the programme rather than as an afterthought. KYSH Labs prepares the dossier, the notification and the labelling alongside the formulation, and produces in Italy to GMP ISO 22716.